Literature DB >> 11091985

Health benefits of oral contraceptives.

J T Jensen1, L Speroff.   

Abstract

A sizeable literature corroborates the multiple health benefits of oral contraceptive use. The first estrogen/progestin combination pills were marketed to treat a variety of menstrual disorders. Although currently used oral contraceptives no longer carry FDA-approved labeling for these indications, they remain important therapeutic options for a variety of gynecologic conditions. Well-established gynecologic benefits include a reduction in dysmenorrhea and menorrhagia, iron-deficiency anemia, ectopic pregnancy, and PID. Although older, higher-dose pills reduced the incidence of ovarian cysts, low-dose pills suppress follicular activity less consistently. Nevertheless, cycle-related symptoms, including functional cysts, dysmenorrhea, chronic pelvic pain, and ovulation pain (mittelschmerz), generally improve. Women with polycystic ovary syndrome note improvement in bleeding patterns and a reduction in acne and hirsutism. Symptoms from endometriosis also improve with oral contraceptive therapy. Current data suggest that oral contraceptive therapy increases bone density and that past use decreases fracture risk. Oral contraceptives also improve acne, a major health concern of young women. Oral contraceptives provide lasting reduction in the risk of two serious gynecologic malignancies--ovarian and endometrial cancer. The data with respect to ovarian cancer are compelling enough to recommend the use of oral contraceptives to women at high risk by virtue of family history, positive carrier status of the BRCA mutations, or nulliparity, even if contraception is not required. Health care providers must counsel women regarding these benefits to counteract deeply held public attitudes and misconceptions regarding oral contraceptive use. Messages should focus on topics of interest to particular groups of women. The fact that oral contraceptives increase bone mineral density and reduce ovarian cancer is of great interest to women in their forties and helps influence use and compliance in this group. In contrast, the beneficial effects of oral contraceptives on acne resonates with younger women. Getting the good news out about the benefits of oral contraceptives will enable more women to take advantage of their positive health effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091985     DOI: 10.1016/s0889-8545(05)70169-8

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  13 in total

Review 1.  Noncontraceptive health benefits of oral contraceptives.

Authors:  Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review.

Authors:  S L Liu; C M Lebrun
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

3.  Giants in Obstetrics and Gynecology Series: A profile of Leon Speroff, MD.

Authors:  Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2017-07-12       Impact factor: 8.661

4.  Oral contraceptive use and depression among adolescents.

Authors:  Sarah McKetta; Katherine M Keyes
Journal:  Ann Epidemiol       Date:  2018-10-13       Impact factor: 3.797

5.  Oral contraceptive use and psychiatric disorders in a nationally representative sample of women.

Authors:  Keely Cheslack-Postava; Katherine M Keyes; Sarah R Lowe; Karestan C Koenen
Journal:  Arch Womens Ment Health       Date:  2014-08-13       Impact factor: 3.633

6.  Is surgical intervention for ectopic pregnancy in a low resource set-up avoidable?

Authors:  Anindita Sinha Babu; Jayeeta Roy; Dipanwita Das; Dipankar Banerjee
Journal:  J Clin Diagn Res       Date:  2014-09-20

7.  Reproductive hormonal treatments for mood disorders in women.

Authors:  Peter J Schmidt; David R Rubinow
Journal:  Dialogues Clin Neurosci       Date:  2002-06       Impact factor: 5.986

8.  The role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice.

Authors:  Min Li; Yang Yu; Jie Yan; Li-Ying Yan; Yue Zhao; Rong Li; Ping Liu; Aaron J Hsueh; Jie Qiao
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

9.  Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway.

Authors:  Yan Li; Yi Jiang; Yicong Wan; Lin Zhang; Weiwei Tang; Jingjing Ma; Shan Wu; Wenjun Cheng
Journal:  J Biomed Res       Date:  2012-12-10

10.  Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review.

Authors:  Alessandra Graziottin
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.